Lund, Sweden, 08.00 CET, March 13, 2019 – BONESUPPORTTM, an emerging leader in orthobiologics for the management of bone voids, today announced the launch of BONIFY™, a demineralized bone matrix (DBM) product line, expanding the company’s product portfolio in the US market. BONIFY will be launched at the American Academy of Orthopedic Surgeons (AAOS) 2019 Annual Meeting in Las Vegas, NV, March 13-15, 2019.
BONIFY is a unique bone graft composed of 100 percent DBM that offers osteoinductive potential to aid in the bone healing process. BONIFY serves to complement the company’s proprietary platform CERAMENT® which offers osteoconductive properties and has been shown to remodel to host bone within 6-12 months.
“These are exciting times for BONESUPPORT. With today’s launch of BONIFY, we are taking an important step in creating a broad and complementary US product offering, expanding our access to a larger segment of the US bone graft market. BONIFY complements CERAMENT® BONE VOID FILLER which we, since October 2018, are selling direct via our own US distributor network”, said Emil Billbäck, CEO of BONESUPPORT.
BONESUPPORT (Nasdaq Stockholm: BONEX) develops and commercializes innovative injectable bio-ceramic bone graft substitutes that remodel to the patient’s own bone and have the capability of eluting drugs. BONESUPPORT’s bone graft substitutes are based on the patented technology platform CERAMENT. The company is conducting several clinical studies to further demonstrate the clinical and health economic benefits its products deliver and a Premarket approval filing with the FDA (USA) for its gentamicin eluting product is planned in 2020. The company is based in Lund, Sweden, and the net sales amounted to SEK 97 million in 2018. Please visit www.bonesupport.com for more information.
BONESUPPORTTM and CERAMENT® are registered trademarks.
For more information contact:
Emil Billbäck, CEO
+46 (0) 46 286 53 70
Håkan Johansson, CFO
+46(0) 46 286 53 70
+46 (0)708 76 87 87